Home › Parkinson's Disease › NCT06455293
Psilocybin Therapy for Depression in Parkinson's Disease
RecruitingPhase 2
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Who can join
Ages 40 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 40 to 80 * Comfortable speaking and writing in English * Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect) * Currently experiencing depressive symptoms * Able to attend all in-person visits at UCSF as well as virtual visits * Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating Exclusion Criteria: * Psychotic symptoms involving loss of insight * Significant cognitive impairment * Regular use of medications that may have problematic interactions with psilocybin * A health condition that makes this study unsafe or unfeasible, determined by study physicians
About the study
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
What is being tested
- Psilocybin (drug)
- Pimavanserin (drug)
Sponsor: Joshua Woolley, MD, PhD · Participants: 60 · Started: Aug 19, 2024
Contact the study team
- Brigette Sosa · Phone: (415) 935-3489
Official record on ClinicalTrials.gov — NCT06455293
Locations in the U.S.
| California | University of California, San Francisco, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.